Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 828 results for "Novartis Company"

GSK Consumer Healthcare chief foresees further industry consolidation
Nikkei Asian Review

GSK and Novartis complete deals to reshape both drugmakers

GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's vaccines business. LONDON: GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that ... Economic Times, 2 months ago

28 images for Novartis Company

Philippine Daily Inquirer, 2 days ago
Reuters, 2 weeks ago
4 Traders, 3 weeks ago
Reuters India, 3 weeks ago
Yahoo! News, 1 month ago
Islamic Republic News Agency, 3 weeks ago
Yahoo!Xtra, 3 weeks ago
Topix, 3 weeks ago
Merced Sun-Star, 3 weeks ago
Rock Hill Herald, 3 weeks ago

Novartis India to consider dividend on May 27, 2015

Novartis India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 27, 2015, to consider approval of audited annual accounts for the year ended March 31, 2015 and recommend dividend for the period mentioned above.
 Money Control1 week ago
Business Standard

Patent refused to Novartis on anti-diabetes formulation

The Patent Office (PO) in Delhi, has refused to grant a patent to Novartis, the Swiss pharmaceutical company, for a modified release formulation of its diabetes drug, Vildagliptin, which it markets under the brand name of Galvus. Novartis has been engaged in ...
 Business Standard1 week ago
EuroInvestor

Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies

/PRNewswire/ -- Today,Novartis announced for the first time detailed results from its phase III EXPEDITION trial program for QVA149 (indacaterol/glycopyrronium) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In the ...
 Tamar Securities5 days ago Novartis' duo of COPD drugs clears Phase III on the path to an FDA decision  FierceBiotech3 days ago Novartis AG (NVS) Reports Two Positive U.S. Phase III Programs in COPD 5/20/2015  ClinicSpace4 days ago Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237  EuroInvestor5 days ago
[x]  

Driven By Pfizer Inc. And Novartis AG (ADR), Global Breast Cancer Drug Sales Expected To Soar By 2020

Global breast cancer branded drug sales may rise to $20 billion in 2020, compared to $13 billion reported in 2014, as per consensus data compiled by Bloomberg Intelligence, which only takes into account currently approved drugs. Roche Holding Ltd.
 Bidness Etc2 days ago Next year's Rolls-Royce Dawn could be the most beautiful Rolls-Royce ever  Mr Top Step1 day ago
Philippine Daily Inquirer

Transforming the way people live with cancer

(First in a series) KETCHUM Research-based Swiss healthcare company Novartis considers Asia an important market. Asia is home to 60 percent of the world population. Almost half of all new cancer cases and slightly more than half of all cancer ...
 Philippine Daily Inquirer3 days ago

Merus Labs Acquires Specialty Product Rights in Multiple Countries

TORONTO The products are being divested by Novartis Pharma AG, a leading global pharmaceutical company for a purchase price of US$29.5 million Salagen ® (pilocarpine hydrochloride) is indicated for xerostomia following radiation therapy, in ...
 Benzinga.com3 days ago Novartis Pharma AG Unloads Certain Specialty Product Rights to Merus for $29.5 Million  BioSpace3 days ago Novartis : Merus Labs to Acquire Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million  4 Traders8 hours ago Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries  News-Medical.Net3 days ago
[x]  

Novartis is updating its Materiality Assessment

This year, Novartis is updating its Coprorate Responsibility Materiality Assessment, which was conducted in 2013. The company is seeking input and perspectives from stakeholders. If you are interested in contributing, please follow this link to ...
 CSR Europe3 days ago

GenVec Q1 net loss increases

GenVec, Inc., a biopharmaceutical company, has reported that net loss for the first quarter ended March 31, 2015 was $1.53 million, or $0.09 loss per share, compared to a net loss of $963,000, or $0.07 loss per share, for the same quarter ended ...
 Individual.com36 minutes ago Ligand Pharmaceuticals reports lower Q1 net income, provides annual outlook  Individual.com4 hours ago

Booster dose

The recent correction presents a good opportunity to buy the stock of Cadila Healthcare. The company's healthy prospects in the US market, thanks to the large pipeline of drugs pending approval by the US drug regulator — Food and Drug ...
 Hindu Business Line1 day ago Cadila Healthcare trumps peers, in talks to acquire Claris Lifesciences for whooping Rs 3,400 crore  Business Insider India4 days ago Cadila Healthcare eyes Claris arm for Rs 3,400 crore  Economic Times4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less